A Randomized, Single Center, Double-blind, Placebo-controlled, First in Human Study With Single Ascending Doses to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Subcutaneous Injections of KINE-101 in Healthy Subjects
Latest Information Update: 27 Jan 2026
At a glance
- Drugs KINE 101 A (Primary) ; KINE 101 A (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Kine Sciences
Most Recent Events
- 27 Jan 2026 New trial record